Rhythm builds case for Phase III in Prader-Willi 

Rhythm is looking toward Phase III development in Prader-Willi syndrome after exploratory Phase II data for MC4R agonist Imcivree showed improvements across weight, body composition, hyperphagia, and behavioral measures. The week also brought clinical setbacks for Elicio and Neumora, with the former company reassessing its pancreatic cancer strategy and the latter abandoning its depression program.

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) announced Monday that a six-month interim analysis of the open-label study demonstrated improvements in Prader-Willi syndrome (PWS) patients receiving once-daily Imcivree setmelanotide, setting up a decision on whether — and with which MC4R agonist — to move into Phase III...